Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
Authors:
- Hagit KopelHKHagit Kopel
- Van Hung NguyenVNVan Hung Nguyen
- Alina BogdanovABAlina Bogdanov
- Isabelle WinerIWIsabelle Winer
- Catherine BoileauCBCatherine Boileau
- Thierry DucruetTDThierry Ducruet
- Ni ZengNZNi Zeng
- Jessamine P. Winer-JonesJWJessamine P. Winer-Jones
- Daina B. EspositoDEDaina B. Esposito
- Mary Bausch-JurkenMBMary Bausch-Jurken
- Ekkehard BeckEBEkkehard Beck
- Machaon BonafedeMBMachaon Bonafede
Open Access
- 27 September 2024
- Vol. 12 (10) , 1107
Abstract
Background/Objectives: This retrospective cohort study evaluated the relative vaccine effectiveness (rVE) of two bivalent (original/Omicron BA.4/BA.5) vaccines mRNA-1273.222 versus the BNT162b2 Bivalent in preventing COVID-19-related outcomes in adults with underlying medical conditions associated with increased risk for severe COVID-19. Methods: In a linked electronic health record/claims dataset, US adults (≥18 years) with ≥1 underlying medical condition of interest who received either the bivalent vaccine between 31 August 2022 and 28 February 2023 were identified. The inverse probability of treatment weighting was used to adjust for cohort differences. Cohorts were followed up for COVID-19-related hospitalizations and outpatient encounters until 31 May 2023. Hazard ratios and rVEs were estimated using Cox regression. Subgroup analyses were performed on individuals with pre-specified comorbid conditions. Results: 757,572 mRNA-1273.222 and 1,204,975 BNT162b2 Bivalent recipients were identified. The adjusted rVE over a median follow-up of 198 days was 10.9% (6.2%–15.2%) against COVID-19-related hospitalization and 3.2% (1.7%–4.7%) against COVID-19-related outpatient encounters. rVE estimates for COVID-19 hospitalizations among subgroups with comorbid conditions were as follows: diabetes 15.1% (8.7%–21.0%), cerebro- and cardiovascular disease 14.7% (9.0%–20.1%), chronic lung disease 11.9% (5.1%–18.2%), immunocompromised 15.0% (7.2%–22.2%), chronic kidney disease 8.4% (0.5%–15.7%). Conclusions: Overall, among adults with underlying medical conditions, mRNA-1273.222 was more effective than BNT162b2 Bivalent, especially in preventing COVID-19-related hospitalizations.Keywords
All Related Versions
Funding Information
- Moderna Inc.
This publication has 32 references indexed in Scilit:
- Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADEInfectious Diseases and Therapy, 2024
- Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)Vaccine, 2023
- Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People With and Without Type 1 DiabetesDiabetes Technology & Therapeutics, 2023
- Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veteransNature Microbiology, 2023
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19New England Journal of Medicine, 2022
- The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variantJournal of Medical Virology, 2022
- Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical ConditionsChest, 2022
- Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19JAMA Network Open, 2020
- Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling studyThe Lancet Global Health, 2020
- Predictors of COVID‐19 severity: A literature reviewReviews in Medical Virology, 2020